Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-10-30 00:00:00 ET · period of report 2024-10-28 · accession 0001415889-24-025792 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-10-30 | 2024-10-28 | JANX | Campbell David Alan | Pres, CEO, Dir | S - Sale | $53.54 | -25.0K | 282.1K | -8% | -$1.34M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-28 | S | D | 13,897 | $53.22 | 293,157 | D | — | — | (F2) The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-10-28 | S | D | 11,103 | $53.94 | 282,054 | D | — | — | (F3) The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |